Enanta Pharmaceuticals Inc. has announced the expansion of its immunology portfolio with the nomination of a new development candidate and the introduction of a new discovery program.
Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.
Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).
Researchers from Pyxis Oncology Inc. presented preclinical data for PYX-201, an antibody drug conjugate (ADC) that targets extra domain B of fibronectin (EDB+FN).
Anocca AB has submitted its first clinical trial application (CTA) to the EMA for a phase I/II multi-asset umbrella trial, VIDAR-1. The application covers ANOC-001 as the initial product in the VIDAR-1 program targeting mutated KRAS in advanced pancreatic cancer.
Longbio Pharma (Suzhou) Co. Ltd. has obtained IND approval from China’s National Medical Products Administration (NMPA) for LP-003, the company’s next-generation anti-IgE antibody, to enter a clinical trial for the treatment of food allergy.
At the Breakthroughs in Muscular Dystrophy special meeting held in Chicago Nov. 19-20, 2024, and organized by the American Society of Gene & Cell Therapy (ASGCT), multiple interventions at the RNA level were among the approaches that were presented to fight muscular dystrophies.
Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation radiopharma imaging and therapy technology targeting fibroblast activation proteins found in a wide range of cancers.
Hebei Wutu Pharmaceutical Co. Ltd. has synthesized transient receptor potential cation channel subfamily V member 4 (TRPV4) antagonists reported to be useful for the treatment of liver cancer, cirrhosis, hepatic fibrosis, chronic hepatitis B and liver failure.
RSS
